Literature DB >> 22205893

Difficulties in achieving arterial hypertension control.

Genel Sur1, Maria Sur, Liana Kudor-Szabadi, Lucia Sur.   

Abstract

OBJECTIVE: Our study aims to examine the effectiveness of arterial hypertension treatment on arterial pressure values in a group of people, by gender and age.
MATERIAL AND METHODS: We performed an analytical prospective study, from 2007 to 2009, that included 2266 people; 674 subjects (397 women and 277 men) were diagnosed with essential systemic arterial hypertension, according to ESH (European Society of Hypertension) criteria. Medium age was 49 years. Therapy applied to all diagnosed patients consisted in: general measures (lifestyle modifications) and pharmacological treatment. Medication regimens implied: one agent (single drug therapy: inhibitors of angiotensin converting enzyme or angiotensin receptors blockers), two, three or more combined drugs (we used a combination of inhibitors of angiotensin converting enzyme or angiotensin receptors blockers and diuretics, beta-blockers, calcium channel blockers). Patients were followed up at 1 month, 3 and 6 month from the beginning of the study. Statistics used was EpiInfo6.
RESULTS: Hypertension control was obtained for 33.38% of all patients; a better control was noticed for feminine gender (35.52%) over masculine gender (30.33%); distribution on age group showed the best control of the disease for the group aged 41 to 60 years old (19.92%) over those aged under 40 years (1.93%) and over 60 years (12.17%).
CONCLUSIONS: Patient's poor compliance to treatment generates a suboptimal hypertension control, emphasizing that efforts for achieving goal blood pressure should continue.

Entities:  

Keywords:  arterial hypertension; control; therapy

Year:  2011        PMID: 22205893      PMCID: PMC3239389     

Source DB:  PubMed          Journal:  Maedica (Buchar)        ISSN: 1841-9038


  38 in total

1.  1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee.

Authors: 
Journal:  J Hypertens       Date:  1999-02       Impact factor: 4.844

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

Review 3.  Diagnosis and management of hypertension in obesity.

Authors:  K Narkiewicz
Journal:  Obes Rev       Date:  2006-05       Impact factor: 9.213

4.  Global burden of hypertension: analysis of worldwide data.

Authors:  Patricia M Kearney; Megan Whelton; Kristi Reynolds; Paul Muntner; Paul K Whelton; Jiang He
Journal:  Lancet       Date:  2005 Jan 15-21       Impact factor: 79.321

Review 5.  Dosage considerations with perindopril for systemic hypertension.

Authors:  D A Sica
Journal:  Am J Cardiol       Date:  2001-10-04       Impact factor: 2.778

6.  Goals and guidelines for treating hypertension in a patient with heart failure.

Authors:  Douglas S Lee; Ramachandran S Vasan
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-08

Review 7.  Hypertension treatment and implications of recent cardiovascular outcome trials.

Authors:  Michael A Weber
Journal:  J Hypertens Suppl       Date:  2006-04

8.  Optimisation of antihypertensive treatment by crossover rotation of four major classes.

Authors:  J E Dickerson; A D Hingorani; M J Ashby; C R Palmer; M J Brown
Journal:  Lancet       Date:  1999-06-12       Impact factor: 79.321

9.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

Review 10.  Worldwide prevalence of hypertension: a systematic review.

Authors:  Patricia M Kearney; Megan Whelton; Kristi Reynolds; Paul K Whelton; Jiang He
Journal:  J Hypertens       Date:  2004-01       Impact factor: 4.844

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.